IFNB1 and neoplasm: However, it will be interesting to compare the efficacy of VSV-GP in future studies with the attenuated VSV variant VSV-IFNβ, which is currently being tested in clinical trials for different tumor entities (ClinicalTrials.gov Identifier: NCT02923466, NCT01628640).